drugset / Trial / NCT04935294
Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
Phase 1
Completed
16 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This was an open-label, nonrandomized, multi-center, single-dose, parallel group study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan (ACH-0144471) compared to demographically-matched healthy participants with normal renal function.
Timeline
- Start
- 2018-01-24
- Primary completion
- 2018-05-29
- Completion
- 2018-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danicopan | Small molecule | 200 mg | Oral |